Discussion
nasopharyngitis, headache
REMISSION, NASOPHARYNGITIS
We have previously shown results from this study in which brazikumab demonstrated efficacy versus placebo; a CDAI response (defined by either a CDAI score of  < 150 or a CDAI reduction from baseline of ≥ 100 points) was achieved by 49.2% of patients receiving brazikumab versus 26.7% of patients receiving placebo at week 8. At week 24, 53.8% of patients in the brazikumab/brazikumab group and 57.7% of patients in the placebo/brazikumab group achieved CDAI response [Recent phase 2/3 studies of other IL-23 inhibitors in patients with CD have shown similar safety profiles. Common TEAEs in a study of mirikizumab over a 52-week period included headache and nasopharyngitis [In addition to the favorable safety profile, longevity of clinical response and remission rates were observed out to week 112 (41.3% and 36.5%, respectively). Although encouraging of a lasting therapeutic benefit to participants, these data should be viewed cautiously given the open-label nature of the extended treatment period and the lack of a placebo control arm for comparison.The current study is one of the longest studies to evaluate the safety of an IL-23 inhibitor in patients with CD. Taken together with long-term risankizumab safety data, these results indicate a consistent safety profile over long-term use for IL-23 inhibitors. Future studies on the safety of brazikumab for a longer treatment duration are warranted. Additionally, further analyses of long-term efficacy of brazikumab are needed.